Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study

BMC Medicine

Research Article

Maria Santucci de Magistris¹  José María Huerta²  Elena Molina-Portillo³  Timothy J. Key⁴  Rosario Tumino⁵  Domenico Palli⁶  Anne Tjonneland⁷  Anja Olsen⁷  Jules Griffin⁸  Pia T. Dinesen⁹  Kim Overvad^1,10  Fulvio Ricceri^1,11  Heiner Boeing^1,12  Matthias B. Schulze^1,13  Janine Kröger^1,13  Kay-Tee Khaw^1,14  Giovanna Tagliabue^1,15  Verena Andrea Katzke^1,16  Tilman Kühn^1,16  Courtney Dow^1,17  Guy Fagherazzi^1,17  Francesca Romana Mancini^1,17  Nadia Slimani^1,18  Peter M. Nilsson^1,19  Paul W. Franks^2,20  Albert Koulman^2,21  Zheng Ye^2,22  Stephen J. Sharp^2,22  Nicholas J. Wareham^2,22  Nita G. Forouhi^2,22  Claudia Langenberg^2,22  Ju-Sheng Zheng^2,22  Fumiaki Imamura^2,22  Annemieke M. W. Spijkerman^2,23  Sandra Colorado-Yohar^2,24  Aurelio Barricarte^2,25  Marcela Guevara^2,25  Jose Ramón Quirós^2,26  Miren Dorronsoro^2,27  Elio Riboli^2,28  Olov Rolandsson^2,29  Antonio Agudo^3,30  Yvonne T. van der Schouw^3,31  Ivonne Sluijs^3,31  Edith J. M. Feskens^3,32 

[1] A.O.U. Federico II, Naples, Italy;CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain;Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain;CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain;Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain;Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK;Cancer Registry and Histopathology Department, “Civic M.P. Arezzo” Hospital, ASP, Ragusa, Italy;Cancer Research and Prevention Institute (ISPO), Florence, Italy;Danish Cancer Society Research Center, Copenhagen, Denmark;Department of Biochemistry, University of Cambridge, Cambridge, UK;Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark;Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark;Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark;Department of Clinical and Biological Sciences, University of Turin, Turin, Italy;Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco, Turin, Italy;Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany;Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany;Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK;Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;German Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany;INSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France;University Paris-Saclay, University Paris-Sud, Villejuif, France;Gustave Roussy, F-94805, Villejuif, France;International Agency for Research on Cancer, Lyon, France;Lund University, Malmö, Sweden;Lund University, Malmö, Sweden;Umeå University, Umeå, Sweden;MRC Elsie Widdowson Laboratory, Cambridge, UK;NIHR BRC Nutritional Biomarker Laboratory, Cambridge, UK;MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, CB2 0QQ, Cambridge, UK;National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands;Navarra Institute for Health Research (ldiSNA), Pamplona, Spain;Research Group on Demography and Health, National Faculty of Public Health, University of Antioquia, Medellín, Colombia;Navarra Public Health Institute (ISPN), Pamplona, Spain;Navarra Institute for Health Research (ldiSNA), Pamplona, Spain;CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain;Public Health Directorate, Asturias, Spain;Public Health Division of Gipuzkoa, San Sebastian, Spain;School of Public Health, Imperial College London, London, UK;Umeå University, Umeå, Sweden;Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain;University Medical Center Utrecht, Utrecht, The Netherlands;Wageningen University, Wageningen, Netherlands;

关键词: Saturated fatty acids;    Odd-chain;    Even-chain;    Very-long-chain;    Metabolic markers;    Lipids;    Hepatic;    Glycaemic;    Inflammation;   

DOI  :  10.1186/s12916-017-0968-4

 received in 2017-06-23, accepted in 2017-10-27,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundAccumulating evidence suggests that individual circulating saturated fatty acids (SFAs) are heterogeneous in their associations with cardio-metabolic diseases, but evidence about associations of SFAs with metabolic markers of different pathogenic pathways is limited. We aimed to examine the associations between plasma phospholipid SFAs and the metabolic markers of lipid, hepatic, glycaemic and inflammation pathways.MethodsWe measured nine individual plasma phospholipid SFAs and derived three SFA groups (odd-chain: C15:0 + C17:0, even-chain: C14:0 + C16:0 + C18:0, and very-long-chain: C20:0 + C22:0 + C23:0 + C24:0) in individuals from the subcohort of the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study across eight European countries. Using linear regression in 15,919 subcohort members, adjusted for potential confounders and corrected for multiple testing, we examined cross-sectional associations of SFAs with 13 metabolic markers. Multiplicative interactions of the three SFA groups with pre-specified factors, including body mass index (BMI) and alcohol consumption, were tested.ResultsHigher levels of odd-chain SFA group were associated with lower levels of major lipids (total cholesterol (TC), triglycerides, apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB)) and hepatic markers (alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT)). Higher even-chain SFA group levels were associated with higher levels of low-density lipoprotein cholesterol (LDL-C), TC/high-density lipoprotein cholesterol (HDL-C) ratio, triglycerides, ApoB, ApoB/A1 ratio, ALT, AST, GGT and CRP, and lower levels of HDL-C and ApoA1. Very-long-chain SFA group levels showed inverse associations with triglycerides, ApoA1 and GGT, and positive associations with TC, LDL-C, TC/HDL-C, ApoB and ApoB/A1. Associations were generally stronger at higher levels of BMI or alcohol consumption.ConclusionsSubtypes of SFAs are associated in a differential way with metabolic markers of lipid metabolism, liver function and chronic inflammation, suggesting that odd-chain SFAs are associated with lower metabolic risk and even-chain SFAs with adverse metabolic risk, whereas mixed findings were obtained for very-long-chain SFAs. The clinical and biochemical implications of these findings may vary by adiposity and alcohol intake.

【 授权许可】

CC BY   
© The Author(s). 2017